A Phase 3 clinical trial, SOTA-EMPA, evaluating Lexicon Pharmaceuticals’ (NASDAQ:LXRX) Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D) met the primary endpoint demonstrating its superiority versus placebo in lowering HbA1C levels at week 26.
A secondary endpoint of non-inferiority to empagliflozin was also met.
No new safety signals were reported.
SOTA-EMPA, conducted by former licensee Sanofi, is the fourth of nine core late-stage studies in the sotagliflozin T2D program.
Complete results will be submitted for presentation at future medical conferences.
Shares up 16% premarket on robust volume.
Update: Shares have reversed, down 6%, apparently due to its failure to demonstrate superiority over Eli Lilly’s (LLY +1.7%) Jardiance (empagliflozin).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.